Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, September 23rd.

Aptevo Therapeutics Stock Performance

Shares of NASDAQ APVO opened at $0.15 on Monday. The firm has a fifty day simple moving average of $0.30 and a two-hundred day simple moving average of $0.77. Aptevo Therapeutics has a 12 month low of $0.14 and a 12 month high of $21.56.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, topping the consensus estimate of ($1.93) by $0.26. As a group, analysts predict that Aptevo Therapeutics will post -2.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.